Nutritional Assessment in Pancreatic Cancer



Rebekah Lord Senior Specialist HPB Dietitian Glenfield Hospital, Leicester






- Normal pancreatic function
- Type 3c Diabetes
- Malnutrition, sarcopenia, cachexia and frailty in pancreatic cancer
- Nutritional requirements
- Assessment tools and functional tests
- Prehabilitation





Pancreas and its functions



Exocrine function (Acinar cells and ducts)

- Produces and secretes enzymes:
 - Lipase (fats)
 - Amylase (carbohydrates)
 - Protease (proteins)


Digestion + absorption

80-90% pancreatic cancer patients display signs of pancreatic exocrine insufficiency





Pancreas and its functions



Endocrine function (Islets of Langerhans)

Produce and secrete hormones into the bloodstream:

- Beta cells Insulin (↓)
- Alpha cells glucagon (个)
- Delta cells Somatostatin

Blood glucose regulation

Type 3c Diabetes





Type 3c Diabetes




Early identification of type 3c Diabetes

- UK-EDI study biomarkers present in newly diagnosed Diabetes with pancreatic cancer
- Earlier diagnosis, treatment options and survival

HbA1c 48mmol/mol

- Masked by PEI
- Average measure 6-8 weeks

National cancer institute, 2021





Yule MS, et al, 2024





Malnutrition in pancreatic cancer

'Malnutrition is a state of nutrition in which a <u>deficiency or excess</u> (or imbalance) of <u>energy, protein and other nutrients</u> causes <u>measurable adverse effects</u> on tissue / body form (body shape, size and composition) and function and clinical outcome.'

More than 1/3 of patients with pancreatic cancer have experienced >10% weight loss at diagnosis

Malnutrition leads to (Gartner et al, 2016):

- Longer Hospital stay
- Increased risk of complications (e.g. infections)
- · Reduced quality of life
- Increased morbidity + mortality
- Poorer outcomes

Early nutritional screening, assessment and Dietetic intervention is crucial

Inadequate nutritional intake

- Increased nutritional requirements (inflammatory response)
- Symptoms; pain, nausea, vomiting, constipation, diarrhoea, taste changes, PEI
 - Prolonged fasting
 - Psychological impact of diagnosis
 - Obstruction
 - Food aversion/restriction



Why is malnutrition common in pancreatic cancer?

Malabsorption/ maldigestion

- Pancreatic exocrine insufficiency
 - Obstructive jaundice
- Misdiagnosed/undiagnosed hyperglycaemia
 - GI resection
- Ischaemia/ileus/delayed gastric emptying
 - Gastric outlet obstruction





Cancer cachexia


Multifactorial syndrome characterised by an <u>ongoing</u> loss of skeletal muscle mass (with or without loss of fat mass) that <u>cannot be fully reversed</u> by conventional nutritional support and leads to progressive functional impairment (Fearon et al, 2011)

- Thought to be present in up to 46-89% of patients with pancreatic cancer (Yule MS, et al, 2024)
- ~40% of patients with pancreatic cancer develop cachexia before surgery (Yule MS, et al, 2024)
- Preoperative cachexia is associated with poorer survival in pancreatic cancer (Bachmann et al, 2009)
- Physical symptoms; muscle wasting, reduced physical activity, negative energy/protein balance, fatigue and social withdrawal
 - Evidence suggests hypothalamic dysfunction (from inflammation) interacts with ghrelin (hunger) + leptin (satiety) contributing to cachexia
- Can have a psychological impact on the families of patients





Cancer cachexia



Fearon et al, 2008





Cancer cachexia management

Prehabiliatation programmes + exercise

Nutrition

- Regular screening + intervention for patients with prognosis >few months (ESMO)
- Artificial feeding not recommended if prognosis <2 months

Psychological support + end of life care

Input from Specialist Nurses and/or palliative care team

Corticosteroids (Dexamethasone/Prednisolone)

- Short term (weeks) improvement of appetite
- Need PPI (to protect stomach) and monitoring of blood glucose levels
- Research has found no effect on body weight

Progesterones (Megastrol acetate)

Appetite stimulant but weight gain rather than lean body mass

Olanzapine (antipsychotic)

 American Society of Clinical Oncology (ASCO) advised low dose once daily can be offered to patients with advanced cancer for nausea + weight gain

MENAC trial





Multimodal intervention - Exercise, Nutrition and Antiinflammary medication for Cachexia

Patients with incurable lung, cholangiocarcinoma or pancreatic cancer for chemotherapy with cachexia (>5% weight loss)

What will help reverse or slow down cachexia?

- Anti-inflammatory medication (high dose fish oil supplements)
- Exercise resistance and aerobic exercise
- Dietetic counselling and ONS

Measured weight, muscle mass, physical function and quality of life at 3, 6 and 12 weeks

Results – patients assigned to multimodal treatment, weight stabilised at 6 weeks compared to standard care. No conclusive difference to muscle mass/physical activity.

Sarcopenia






"Progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality" (Cruz-Jentoft et al, 2018)

Prevalence of **55.9%-63%** reported in pancreatic cancer patients

High BMI can mask sarcopenia



(Martin L et al, 2013)





Sarcopenia in pancreatic cancer

Patients with advanced pancreatic cancer undergoing Folfirinox *chemotherapy* had (Kurita et al, 2019):

- Poorer outcomes/worse overall survival if sarcopenic
- Increased toxicities from treatment with sarcopenic obesity

Surgical patients

- Increase in perioperative and overall mortality if sarcopenic (Bundred et al, 2019)
- If sarcopenic, significantly reduced survival and higher complication rate when undergoing resection for pancreatic ductal adenocarcinoma





Sarcopenia management

- Protein intake aim 1-1.5g/kg/day
- Benefits to increasing activity levels
 - HIIT, aerobic, resistance
- Vitamin D increases muscle strength, reverses muscle atrophy

FEED study - Effectiveness of a 12 week multi-modal nutrition-led intervention in preventing loss of muscle strength during neo-adjuvant chemotherapy

Fish oil, Exercise, Enzyme, Dietary Counselling
FEED trial – RCT with control group + intervention (additional Dietitian and Physiotherapy appointments)





Frailty

"A person's mental and physical resilience, or their ability to bounce back and recover from events like illness and injury." Age UK

Prevalence in pancreatic cancer is 45% (Zhang F, Yan Y, Ge C, 2024)

Associated with an increased risk of mortality (Zhang F, Yan Y, Ge C, 2024)


Clinical frailty scale score

Interventions can help to reduce frailty:

- Exercise to improve strength and balance
- Addressing nutritional deficiencies

Clinical Frailty Scale*











6 Moderately Frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressine.



7 Severely Frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).





9. Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.

Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia. Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

* I. Canadian Study on Health & Aging, Revised 2008.
2. K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. CMAI 2005;173:489-495.

Ø 2007-2009. Version 1.2. All rights reserved. Geniatric Me Research, Dalhousie University Halifax, Canada. Permission to copy for research and educational purposes only.







Nutritional requirements in pancreatic cancer

ESPEN guidelines (2016)

Energy

- 25-30kcal/kg/day
- Evidence level: low

Protein

- 1-1.5g/kg/day
- Evidence level: moderate

PENG (2018)

Energy

- 24kcal/kg/day
 - ≤65 yrs
 - (BMI 18.5-30kg/m²)
- 24kcal/kg/day (range 22-27)
 - > 65 yrs
 - (BMI 18.5-30kg/m²)
- 25kcal/kg/day (range 24-26)
 - (BMI<18.5kg/m²)

Protein

- Based on ESPEN guidelines
- 1-1.5g/kg/day



What nutritional assessment do you regularly use for patients with pancreatic cancer?




How do we assess risk of malnutrition?





Screening tools



Malnutrition Universal Screening Tool (MUST)

Widely used in many Hospitals Considers BMI, weight loss and acute illness

BUT

- Lower sensitivity in oncology patients
- Does not consider if treatment is likely to affect nutritional status
- Does not consider sarcopenia or nutrition impact symptoms
- Early intervention is key



Patient ID Information



Scored Patient Generated Subjective Global **Assessment** (PG-SGA)

Scored Patient-Generated Subjective Global Assessment (PG-SGA)

While height is not essential for scoring, the app calculates BMI

use 1 mo if available.

pounds

pounds

Use 6 mos only if 1 mo is not available

History Boxes 1-4 are designed to be completed by the patient. [Boxes 1-4 are referred to as the PG-SGA Short Form (SF)]

pounds

Pt should complete if possible: not professional or family unless needs help (sight, literacy, etc.)

4. Activities and Function:

normal with no limitations

2. Food Intake: As compared to my rate my food intake during the pa	-
unchanged more than usual less than usual less than usual	Score how the patient self-rates his/her intake during the past month; this helps to address recent deficit / current risk
I am now taking:	
normal food but less than	normal amount
little solid food	(1)
only liquids	
only nutritional suppleme	ents ₍₃₎
very little of anything	
(4)	
only tube feedings or only	y nutrition by vein Box 2
Box 2 not additive: max = 4: use the highest score of	necked, no matter how many checked

During the past tw	o weeks my wei	ght has:					
□ decreased _□ □	□ decreased □ not changed □ increased □ Box 1						
Box 1 max score = 5 points:	up to 4 pts from wt lo	ss + up to 1 point for past 2 v	wks				
 Symptoms: I have from eating enough no problems eating 	during the past	g problems that have two weeks (check all					
 no appetite, just 	did not feel like						
nausea (1) constipation		ovomiting (1)					
mouth sores (2) things taste funn problems swallov pain; where? other**	wing (2)	feel full quie	er me (1)				
** Examples: de	pression, money,	or dental problems					
	Box 3 Any symptoms that patient reports (checks off) that has kept them from eating enough during the past 2 weeks gets scored. Add all points for Box 3 total score						

	Additive Score of the Boxes	s 1-4 A
rates his/her activity level inadequate intake, metabo trauma) or significant inac	performance status in patient terms, Patient over the past month regardless of the cause – olic stress (cordicosteroids, fever, inflammation, tivity, Remember, 1 week of complete bed rest is oss in lean tissue/muscle mass	Box 4
	e activity and spend most of the day in edridden, rarely out of bed	bed or chair
activities not feeling up	l self, but able to be up and about with to most things, but in bed or chair less	-

Over the past month, I would generally rate my activity as:

©FD Ottery, 2001, 2005, 2006, 2014

1. Weight (See Worksheet 1)

I currently weigh about

One month ago I weighed about

Six months ago I weighed about

I am about

In summary of my current and recent weight:

Email: faithotterymdphd@aol.com or info@pt-global.org



		S
	ļ	ľ
	c	H

The remainder of this form is to be completed by your doctor, nurse, dietitian, or therapist. Thank you.

		Scor	ed P	atient	-Gene	rated S	Subjectiv	e Gle	obal Ass	essme	nt (PG-SGA	4)		
To determine there is no 1	e score, use 1 mont month weight data	Weight (Wt) h weight data if avail . Use points below the weight during the particular	Loss lable. Us to score v	e 6 month d	ata only if	5. Works	sheet 2 - D	isease a	Additive and its rela	Score	of the Boxes nutritional requ	1-4 (See Side 1)] 1
Wt loss in	1 month Poin	ts Wt loss in 6	months				evant diagno							
10% a	r greater 4		6 or gre	ater		Primar	y disease sta	ige (cin	cle if know	n or appi	ropriate) I II III	IV Other		
5-9.9			19.9%			One point	each:							
3-4.9° 2-2.9°			- 9.9% - 5.9%					□Pulm	onarvorcardi	accachexi	a Presence of de	ecubitus, open wou	nd, or fist	ula
0-1.9	/0		- 1.9%					_	greater than 6		Chronic renal		,	
	Numerical	score from V	Vorksl	heet 1						Nume	erical score from	m Worksheet 2		
6. Work	Sheet 3 - M	etabolic Den	nand											_
Score for	metabolic stress	is determined b	y a nun	nber of va	riables kn	own to incre	ease protein &	calorie 1	needs. The sc	ore is addi	itive so that a patier	nt who has a fever	of > 102	2
degrees (3	points) and is	on 10 mg of prec	Inisone	chronical	ly (2 point	s) would ha	ive an additive	score fo	or this section	of 5 point	Fever: Score fever	intensity or duration,	whicheve	is
Stress		one (0)	low (1			noderate (2)			high (3)			2°C 101°=38.3° and		
Fever	no	fever	>99	and <101		>101 and <1	.02		>102	Num	ericai score iro	m worksneet 3		J
Fever dur		fever	<72 h			72 hrs			> 72 hrs		Con unou at alabal	org for prednisone		1
Corticoste	roids no	corticosteroids	low d			moderate do			high dose st			nd metric and addition	nal	
	use of corticostero protein status an			ig prednis iivalents/c		(>10 and <3 equivalen	Omg prednisor	ie	(> 30mg pred equivalents		language version (a			
interosseous thigh (quadi Global orbital fat p triceps skin	ectoralis & deltoids s muscles triceps) muscle status rati	0	1+ 1+ 1+ 1+ 1+ 1+	2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+	3+ 3+ 3+ 3+ 3+ 3+ 3+	can/should determining fluid). REL have to ass a global ser muscle or f maximum p exam is onl not likely to point	examples of are be considered is loss/defloit (or loss or does as all of these sess all of these has the core for play 3 points and y 3 points and y be off by more	n excess NOT to have efficit of he hysical rou are than 1	Ì	l numer (See	3+ 3+ Total PG- ical score of A- triage recommental PG-SGA ratio	-SGA score +B+C+D above ndations below)	, 🗀	
	_	GI I I I				_								_
	Stare A	A Global Asses	Sta	IPE C.							re is used to define speci		ons	
Weight	Well nourished No wt loss	Moderately malnourished 5% wt loss in 1 month	> 5	erely malnourish % wt loss in 1 m	onth		nationt & family of tervention (food, r				g pharmacologic interve	muon, and appropriate		
	OR Recent wt gain	(or 10% in 6 mos) OR Progressive wt loss	(or	>10% in 6 mos) Progressive wt			nutrition interven							
	No deficit OR Significant recent	Definite decrease in intak		ere deficit in int										
Nutrition Impact		Present of nutrition impa		sent of nutrition		0-1	No intervention			essment on n	outine and regular basis	during treatment.		
	OR Significant recent improvement allowing	symptoms (PG-SGA Box	(3) sym	ptoms (PG-SG/	Hox 3)	2-3					nician with pharmacolog			
	No deficit OR	Moderate functional defi-	cit Sev	ere functional de	ficit		indicated by sym	iptom surve	ey (Box 3) and lal	values as ap	propriate.			
	Recent improvement No deficit OR	Evidence of mild to mod	erate Obvi	ious sions of ma	nutrition	4-8					se or physician as indica		3).	
	Chronic deficient but	loss of muscle mass / SQ atmuscle tone on pulpation	fat / (c.g.	,, severe loss mu suble edema)	sele, SQ	<u>> 9</u>	Indicates a critica	il need for i	improved sympto	m manageme	ent and/or nutrient interv	ention options.		
Physical Exam	Recent improvement No deficit OR Chronic deficient but tissue, recent improveme	OR Recent deterioration Evidence of mild to mod loss of muscle mass / SQ	erate Obvi fat / (e.g. po	t recent significations signs of main, severe loss mustible edema)	nt deterioration instrition sele, SQ	<u>> 9</u>	Requires interve Indicates a critica	ntion by die al need for i	etitian, in conjunc	tion with nur			3).	_

Vashi et al — "Improvement in SGA correlated with a significantly decreased risk of mortality independent of sex, previous treatment history, and evidence of biological anticancer activity."

MALNUTRITION SCREENING TOOL (MST)

STEP 1 QUESTION A & QUESTION B

Emphasize "without trying"
Consider weight lost during the last -6 months
. If the person is unsure query any indicators of
weight loss such as:
» Loose clothes or using a tighter belt notch
» Loose rings/jewellery or watches
» Ill-fitting dentures
- In Hong Commes
* See below for approximate kilogram (kg) to pounds (lbs) conversion chart.
Emphasize "eating poorty", e.g. eating less than 3/4 of usual intake.
 Is intake likely to decrease considerably for 5 days or more?
 If re-screening, have staff noted poor food intake over the past week?

Add Weight	Loss &	Appetite	Scores
------------	--------	----------	--------

Total MST Score:

- · Document malnutrition risk category (even for those not at risk).
- · Record any need for special diets and follow local policy.

MST Score 2 or more = Patient is at risk of malnutrition

STEP 3 MANAGEMENT PLAN

Score 0-1: Monitor weight and re-screen weekly or in line with local policy.

Score 2 or more: Monitor nutritional intake, use strategies to improve nutritional intake and refer to dietitian or implement local policy.

- . Those who are overweight or obese MUST NOT be overlooked in the diagnosis and prevention of malnutrition.
- · All patients should be screened on admission to hospital and weekly (or as per local policy) thereafter.

Approximate Weight Conversion Chart

Kilograms	Pounds	Score
1-5 kg	2-11 lbs	1
6-10 kg	12-22 lbs	2
11-15kg	23-33 lbs	3
>15 kg	> 33 lbs	4

Note: 14 lbs = 1 stone

Ferguson M, et al. Development of a valid and reliable malhotribon acreeming tool for adult acute hospital patients. Notrition. 1999;15(6):458-464. Department of Health (2020), Nutrition screening and use of one nutrition support for edults in the acute care setting, (INCEC National Clinical Guideline No. 22).

Nutricia, Block 1, Deansgrange Business Park, Deansgrange, Co. Dublin. NUTRICIA CUSTOMER SUPPORT:

Freephone: 1800 923 404 (ROI) or 0800 783 4379 (NI) Email: support ineland (constrict a com-This information is intended for healthcare professionals only www.nutricia.ie







Royal Marsden Nutrition Screening Tool (RMNST)

Question	If answer to the question is yes, then score
Has the patient experienced unintentional weight loss in the last 3 months?	
(>7 kg in men or >5.5 kg in women)	10
If not, unintentional weight loss less than the above	5
2. Does the patient look underweight?	5
3. Has the patient had a reduced food intake (less than 50 % of meals) in the last 5 days (this may be due to mucositis, dysphagia, nausea, bowel obstruction, vomiting)?	5
Is the patient experiencing symptoms that are affecting food intake, e.g. mucositis, nausea, vomiting, diarrhoea and constipation?	3
Total score	Maximum 23

Copyright The Royal Marsden NHS Foundation Trust

Score 0-4, well-nourished, score 5-9, moderately malnourished, score >10, severely malnourished






How do we assess <u>cachexia</u>?





Global Leadership Initiative on Malnutrition (GLIM) criteria for malnutrition


Calf circumference						
Males Females						
Moderate	34cm	33cm				
Severe 32cm 31cm						








How do we assess <u>sarcopenia</u>?





Cruz-Jentoff et al, 2019







Cruz-Jentoff et al, 2019





How do we assess **frailty**?





- Gait speed
- Timed-up-and-go test
- PRISMA questionnaire
 - 7 questions age, gender, health problems limiting activities/requiring patient to stay at home, support, if use aids to get about
- Self-Reported Health 'How would you rate your health on a scale of 0-10'.



Other assessment tools

- Faecal elastase-1
- DEXA bone mineral density scan every 2 years for patients with PEI
- Assessment of nutritional deficiencies
 - Fat soluble vitamins (A, D, E + K), Vitamin B12, Folate, Iron studies, Zinc, Selenium, Copper, Magnesium
 - HbA1c, random blood glucose every 6-12 months
 - Palliative patients Iron studies, HbA1c, random blood glucose

- Gastrointestinal symptoms
- Quality of life
- Knowledge of PERT





Prehabilitation

- "Prehabilitation enables people with cancer to prepare for treatment
 through promoting healthy behaviours and through needs based
 prescribing of exercise, nutrition and psychological interventions.
 Prehabilitation is part of a continuum to rehabilitation. The aims of
 prehabilitation are to empower patients to maximise resilience to
 treatment and improve long-term health" (Macmillan pinciples and guidance
 for prehabilitation within the management and support of people with cancer)
- Early assessment soon after diagnosis
- Benefits include;

Personal empowerment

Physical and psychological resilience

Long term health


Reversal of sarcopenia

Better mental health





Prehabilitation



Tew GA et al, 2018





Prehabilitation





ORIGINAL ARTICLE

From prehab to rehab: Nutritional support for people undergoing pancreatic cancer surgery

Neil Bibby, Azita Rajai, Derek A. O'Reilly 🔀

First published: 23 May 2022 | https://doi.org/10.1111/jhn.13040 | Citations: 3

- Prospective study of 150 patients
 - Baseline dietetic assessment, prehabilitation and at least one post-operative review
- High prevalence of malnutrition
 - 2/3 of patients had experienced >5% weight loss, 1/3 of patients had experienced >10% weight loss
- Gained 2% body weight and improved handgrip strength by 8.2%
- PG-SGA scores reduced by 5.9 and GI symptom rating scale by 47.7%





To conclude...

 Assessment of nutritional status in pancreatic cancer is extremely complex and multifactorial

- Early nutritional screening is important, as well as identifying cachexia and sarcopenia to allow for early dietetic intervention and/or referral to prehabilitation services
 - Early development of treatment plans can improve survival, outcomes and tolerance to treatment

References





Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.

Could a Diabetes Diagnosis Help Detect Pancreatic Cancer Early? (2021) National cancer institute. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2021/pancreatic-cancer-diabetes-early-detection (accessed 19 November 2024)

Yule MS, Brown LR, Waller R, Wigmore SJ. Cancer cachexia. BMJ 2024;387:e080040

Gärtner S, Krüger J, Aghdassi AA, et al. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors. 2016;2(4):195-202. doi:10.1159/000442873

Fearon KCH, Baracos VE: Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford) 2010;12:323–324.

Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME: Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12:1193–1201.

Solheim TS, Laird BJA, Balstad TR, et al. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care2018;8:258-65. doi:10.1136/bmjspcare-2017-001440 pmid:29440149

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034.

Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25. PMID: 23530101.

Kurita Y, Kobayashi N, Tokuhisa M, Goto A, Kubota K, Endo I, Nakajima A, Ichikawa Y. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019 Jan;19(1):127-135. doi: 10.1016/j.pan.2018.11.001. Epub 2018 Nov 10. PMID: 30473464.

Bundred J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford). 2019 Dec;21(12):1603-1612. doi: 10.1016/j.hpb.2019.05.018. Epub 2019 Jun 29. PMID: 31266698.

Zhang F, Yan Y, Ge C. Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients. Ann Surg Oncol. 2024 Jan;31(1):535-544. doi: 10.1245/s10434-023-14426-y. Epub 2023 Oct 29. PMID: 37899415.

Vashi P, Popiel B, Lammersfeld C, Gupta D. Outcomes of systematic nutritional assessment and medical nutrition therapy in pancreatic cancer. Pancreas. 2015 Jul;44(5):750-5. doi: 10.1097/MPA.00000000000336. PMID: 25872172

Tew GA, Ayyash R, Durrand J, Danjoux GR et al. Clinical guideline and recommendations on pre-operative exercise training in patients awaiting major non-cardiac surgery. Anaesthesia 2018;73(7):750-68

Bibby N, Rajai A, O'Reilly DA. From prehab to rehab: nutritional support for people undergoing pancreatic cancer surgery. J Hum Nutr Diet. 2022:1-11. https://doi.org/10.1111/jhn.13040